Abaxis Declares Quarterly Cash Dividend

 

UNION CITY, Calif., Nov. 3, 2015 /PRNewswire/ -- The Board of Directors of Abaxis, Inc. (NasdaqGS: ABAX), has declared a cash dividend of $0.11 per common share. The dividend will be payable on December 17, 2015 to all shareholders of record at the close of business on December 3, 2015.

Abaxis' previous quarterly dividend of $0.11 per common share was paid on September 17, 2015. Future dividends will be subject to approval by our Board of Directors.

About Abaxis

Abaxis, Inc. is a worldwide developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. Our mission is to improve the efficiency of care delivery to and the quality of life of patients in the medical and veterinary markets. We provide leading edge technology and tools that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. For more information, visit http://www.abaxis.com.

Contact:

Abaxis, Inc.

Lytham Partners, LLC

 

Clint Severson

Joe Dorame, Robert Blum and Joe Diaz

 

Chief Executive Officer

602-889-9700

 

510-675-6500

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abaxis-declares-quarterly-cash-dividend-300171010.html

SOURCE Abaxis, Inc.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…